Ngenla (Somatrogon)

Somatrogon binds to growth‑hormone receptors, stimulating hepatic production of insulin‑like growth factor‑1 (IGF‑1), which promotes bone and tissue growth. Its fusion protein structure prolongs circulation, allowing once‑weekly subcutaneous dosing.

The dosage of Ngenla is individualized by the prescribing clinician based on the child’s weight, age, IGF‑1 levels and growth response. Dosing is typically administered once weekly by subcutaneous injection, with adjustments made during follow‑up visits.

Safety of somatrogon in pregnant or nursing women has not been established. It is generally reserved for pediatric patients, and use in women of childbearing potential should be avoided unless the potential benefit justifies the risk.

To request Ngenla, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and necessary import documentation.

Ngenla (somatrogon) is a long‑acting recombinant growth hormone that allows once‑weekly dosing, whereas traditional somatropin products require daily injections. Clinical studies show comparable efficacy in height velocity, with the convenience of fewer injections potentially improving adherence.

Ngenla must be stored refrigerated between 2 °C and 8 °C. Keep the vial in its original carton, protect it from light, and do not freeze or shake the solution. If a dose is not used within the recommended time after reconstitution, discard it according to local regulations.

Ngenla is given as a subcutaneous injection, usually into the thigh or abdomen, once each week. The injection site should be rotated to reduce local reactions, and the dose is prepared according to the manufacturer’s instructions using aseptic technique.

Serious adverse events reported with somatrogon include intracranial hypertension, slipped capital femoral epiphysis, severe allergic reactions, and abnormal glucose metabolism. Patients should be monitored for persistent headaches, visual disturbances, joint pain, and signs of hyperglycemia, and any concerning symptoms should prompt immediate medical evaluation.

Ngenla is contraindicated in patients with active malignancy, known hypersensitivity to somatrogon or any excipients, and in children with closed epiphyses where further growth is not possible. Caution is also advised for individuals with uncontrolled diabetes or severe scoliosis.